Rescue Your Trial Before It's Too Late.
Biorasi Can Help You To Evaluate and Save A Faltering Program
More than 30% of all clinical trials currently running for FDA or EMA approval are in danger of missing deadlines or milestones. These clinical studies experience problems for a wide variety of reasons.
- Study design issues, potential data quality problems
- Long term impact and root causes of under-enrollment
- Projected budget overruns, logistics failures
- Projected timeline delays, missed milestone
Solving at Risk Trials White Paper: 3 Measures to Overcome Operational Failures
Dive into why clinical trials falter and what can be done to prevent those trials from becoming “Operational Failures”. Learn how to recognize and react to under performing trials, specific signs that indicate a trial may be in danger of failure, and the intervention options available to correct the deficiencies.